Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778468 | 0.81 | HTT (0.51) | HTTDDB1CRBNHCAR1GPR119 | |
| SCHEMBL8718367 | 0.81 | HTT (0.51) | HTTGPR119ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7028939 | 0.79 | HTT (0.50) | HTTHCAR1GPR119ALDH1A1PKM | |
| SCHEMBL1618003 | 0.79 | HTT (0.50) | HTTHCAR1GPR119ALDH1A1SMN1; SMN2 | |
| SCHEMBL8718617 | 0.79 | HTT (0.54) | HTTHCAR1GPR119TDP1RAB9A | |
| SCHEMBL8718822 | 0.79 | HTT (0.50) | HTTGAAGPR119ALDH1A1SMN1; SMN2 | |
| SCHEMBL792758 | 0.79 | HTT (0.50) | HTTGAAGSK3AGSK3BHCAR1 | |
| SCHEMBL17202641 | 0.79 | HTT (0.46) | HTTGPR119ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6173722 | 0.78 | RAB9A (0.60) | GAASMN1; SMN2LMNAPKMCYP1A2 | |
| SCHEMBL1786748 | 0.77 | HTT (0.60) | HTTGAAGSK3AGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7906548-B2 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100069385-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (NJ) | 2010-03-18 | — | — | US | disclosed |
| US-20100035957-A1 | Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 | WYETH | 2010-02-11 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7605156-B2 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| US-5728834-A | Process for preparation of 4-aryl-1,2,4-triazol-3-ones | WYCKOFF CHEMICAL COMPANY, INC. (US) | 1998-03-17 | — | — | US | disclosed |
| US-4350701-A | 1-(Trihalomethyl-sulfenyl)-4-aryl-1,2,4-triazolin-5-ones, and process for controlling fungi | BASF AKTIENGESELLSCHAFT (DE) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | PLA2G12A, PLA2G1B, PLA2G5 | HTT 3375/4885DDB1 4271/4885CRBN 4714/4885 |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | HTT 2418/4885DDB1 3823/4885CRBN 4146/4885 |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G4B, PLA2G4A, PLA2G1B | HTT 4455/4885DDB1 3983/4885CRBN 4432/4885 |
| US-20100069385-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G2D, PLA2G4B, PLA2G4A | HTT 4416/4885DDB1 4128/4885CRBN 4499/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | HTT 2418/4885DDB1 3823/4885CRBN 4146/4885 |
| US-20100035957-A1 | Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G1B | HTT 2770/4885DDB1 4154/4885CRBN 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.